Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03434028 · ClinicalTrials.gov registry record · Phase 3
Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis
A Phase 3 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,563
- Enrollment target
NCT03434028: Completed Phase 3 study, sponsored by Massachusetts General Hospital.
NCT03434028 is a Phase 3 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 1,563 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03434028, a Phase 3 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,563 participants
- Enrollment target
Study Summary
Multicenter, prospective, phase 3 randomized non-blinded interventional trial of fluid treatment strategies in the first 24 hours for patients with sepsis-induced hypotension. The aim of the study is to determine the impact of a restrictive fluids strategy (vasopressors first followed by rescue fluids) as compared to a liberal fluid strategy (fluids first followed by rescue vasopressors) on 90-day in-hospital mortality in patients with sepsis-induced hypotension.
Interventions
- DRUG Early Vasopressors
- OTHER Early Fluids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,563 participants |
| Start Date | 2018-03-07 |
| Est. Completion | 2022-08-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03434028
The ClinicalTrials.gov registry entry for NCT03434028 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,563 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Early Vasopressors is the first listed.
NCT03434028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03434028 about?
NCT03434028 is a clinical study titled "Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis". Multicenter, prospective, phase 3 randomized non-blinded interventional trial of fluid treatment strategies in the first 24 hours for patients with sepsis-induced hypotension. The aim of the study is to determine the impact of a restrictive fluids strategy (vasopressors first followed by rescue flui...
What is the current status of trial NCT03434028?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,563 participants. The study started on 2018-03-07. Estimated completion is 2022-08-24.
What interventions are being tested in trial NCT03434028?
The interventions under investigation include: Early Vasopressors (DRUG), Early Fluids (OTHER).
Who is sponsoring clinical trial NCT03434028?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.